Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets

Trends in Parasitology

Volumn 20, Issue 8, 2004, Pages 381-387

  Das, Aditi ^a   Dasgupta, Arindam ^b   Sengupta, Tanushri ^c   Majumder, Hemanta K ^c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; ACRIDINE DERIVATIVE; ALKALOID DERIVATIVE; AMSACRINE; ANTHRACYCLINE; ANTIBIOTIC AGENT; BENZOPHENAZINE; BIS(2,6 DIOXOPIPERAZINE); CAMPTOTHECIN; COUMARIN DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELLIPTICINE DERIVATIVE; ETOPOSIDE; FLAVONOID; FOSTRIECIN; GYRASE INHIBITOR; INDOLOCARBAZOLE; MAKALUVAMINE; MERBARONE; PIPERAZINEDIONE; PODOPHYLLOTOXIN DERIVATIVE; QUINOLINE; QUINOLONE DERIVATIVE; SURAMIN; TENIPOSIDE; TERPENOID DERIVATIVE; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARBOXY TERMINAL SEQUENCE; CHROMOSOME MAP; CRITHIDIA; CRYSTAL STRUCTURE; DNA HELIX; ERYTHROCYTE; EUKARYOTE EVOLUTION; FLAGELLATE; GENE LOCATION; LEISHMANIA; LEUKEMIA CELL; LIFE CYCLE; NONHUMAN; REVIEW; TRYPANOSOMA; YEAST;

ANIMALS; ANTIPROTOZOAL AGENTS; DNA TOPOISOMERASES; HUMANS; KINETOPLASTIDA; LEISHMANIASIS; MODELS, MOLECULAR; PHYLOGENY; TRYPANOSOMIASIS;

CRITHIDIA; EUKARYOTA; KINETOPLASTIDA; MASTIGOPHORA (FLAGELLATES); PROTOZOA; TRYPANOSOMA;

EID: 3142710896     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2004.06.005     Document Type: Review

References (69)

1. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3:2002;430-440
2. Cortes F., et al. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat. Res. 543:2003;59-66
3. Champoux J.J. DNA topoisomerases: structure, function and mechanism. Annu. Rev. Biochem. 70:2001;369-413
4. Bjornsti M.A., Wang J.C. Expression of yeast DNA topoisomerase I can complement a conditional-lethal DNA topoisomerase I mutation in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 84:1987;8971-8975
5. Stewart L., et al. Reconstitution of human topoisomerase I by fragment complementation. J. Mol. Biol. 269:1997;355-372
6. Berger J.M. Structure of DNA topoisomerases. Biochim. Biophys. Acta. 1400:1998;3-18
7. Bakshi R.P., et al. Functional and regulatory characteristics of eukaryotic type II DNA topoisomerases. Crit. Rev. Biochem. Mol. Biol. 36:2001;1-37
8. Wang J.C. DNA topoisomerases: why so many? J. Biol. Chem. 266:1991;6659-6662
9. Broxterman H.J., Georgopapadakou N. Cancer research 2001: drug resistance, new targets and drug combinations. Drug Resist. Updat. 4:2001;197-209
10. Nitiss J.L. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr. Opin. Investig. Drugs. 3:2002;1512-1516
11. Denny W.A., Baguley B.C. Dual topoisomerase I/II inhibitors in cancer therapy. Curr. Top. Med. Chem. 3:2003;339-353
12. Shapiro T.A. Inhibition of topoisomerases in African trypanosomes. Acta Trop. 54:1993;251-260
13. Bodley A.L., et al. Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem. Pharmacol. 50:1995;937-942
14. Bearden D.T., Danziger L.H. Mechanism of action of and resistance to quinolones. Pharmacotherapy. 21:2001;224S-232S
15. Chakraborty A.K., Majumder H.K. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem. Biophys. Res. Commun. 152:1988;605-611
16. Chakraborty A.K., et al. A type I DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Indian J. Biochem. Biophys. 30:1993;257-263
17. Riou G.F., et al. A type I DNA topoisomerase from Trypanosoma cruzi. Eur. J. Biochem. 134:1983;479-484
18. Melendy T., Ray D.S. Purification and nuclear localization of type I topoisomerase from Crithidia fasciculata. Mol. Biochem. Parasitol. 24:1987;215-225
19. Bodley A.L., Shapiro T.A. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc. Natl. Acad. Sci. U. S. A. 92:1995;3726-3730
20. Das B.B., et al. Reconstitution and functional characterization of bi-subunit topoisomerase I from Leishmania donovani. FEBS Lett. 565:2004;81-88
21. Broccoli S., et al. Characterization of a Leishmania donovani gene encoding a protein that closely resembles a type IB topoisomerase. Nucleic Acids Res. 27:1999;2745-2752
22. Villa H., et al. A novel active DNA topoisomerase I in Leishmania donovani. J. Biol. Chem. 278:2003;3521-3526
23. Bodley A.L., et al. An unusal type IB topoisomerase from African Trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 100:2003;7539-7544
24. Melendy T., Ray D.S. Novobiocin affinity purification of a mitochondrial type II topoisomerase from the trypanosomatid Crithidia fasciculata. J. Biol. Chem. 264:1989;1870-1876
25. Shlomai J., Zadok A. Reversible decatenation of kinetoplast DNA by a DNA topoisomerase from trypanosomatids. Nucleic Acids Res. 11:1983;4019-4034
26. Shlomai J., et al. A unique ATP-dependent DNA topoisomerase from trypanosomatids. Adv. Exp. Med. Biol. 179:1984;409-422
27. Douc-Rasy S., et al. ATP independent type II topoisomerase from trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 83:1986;7152-7156
28. Chakraborty A.K., Majumder H.K. Decatenation of kinetoplast DNA by an ATP-dependent DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Mol. Biochem. Parasitol. 26:1987;215-224
29. Chakraborty A.K., Majumder H.K. An ATP independent catenating enzyme from the kinetoplast hemoflagellate Leishmania donovani. Biochem. Biophys. Res. Commun. 180:1991;279-285
30. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 54:1985;665-697
31. Melendy T., et al. Localization of a type II DNA topoisomerase to two sites at the periphery of the kinetoplast DNA of Crithidia fasciculata. Cell. 55:1988;1083-1088
32. Pasion S.G., et al. Molecular cloning and expression of the gene encoding the kinetoplast-associated type II DNA topoisomerase of Crithidia fasciculata. Mol. Biochem. Parasitol. 50:1992;57-68
33. Das A., et al. Characterization of the gene encoding type II DNA topoisomerase from Leishmania donovani: a key molecular target in antileishmanial therapy. Nucleic Acids Res. 29:2001;1844-1851
34. Strauss P.R., Wang J.C. The TOP2 gene of Trypanosoma brucei: a single copy gene that shares extensive homology with other TOP2 genes encoding eukaryotic DNA topoisomerase II. Mol. Biochem. Parasitol. 38:1990;141-150
35. Fragoso S.P., Goldenberg S. Cloning and characterization of the gene encoding Trypanosoma cruzi DNA topoisomerase II. Mol. Biochem. Parasitol. 55:1992;127-134
36. Gaziova I., Lukes J. Mitochondrial and nuclear localization of topoisomerase II in the flagellate Bodo saltans (Kinetoplastida), a species with non-catenated kinetoplast DNA. J. Biol. Chem. 278:2003;10900-10907
37. Sengupta T., et al. Functional dissection of the C-terminal domain of the type II topoisomerase of the kinetoplastid hemoflagellate Leishmania donovani. Nucleic Acids Res. 31:2003;5305-5316
38. Hanke T., et al. Cloning, functional analysis and post-transcriptional regulation of a type II DNA topoisomerase from Leishmania infantum. A new potential target for anti-parasite drugs. Nucleic Acids Res. 31:2003;4917-4928
39. Fragoso S.P., et al. Expression and cellular localization of Trypanosoma cruzi type II DNA topoisomerase. Mol. Biochem. Parasitol. 94:1998;197-204
40. Johnson C.E., Englund P.T. Changes in organization of Crithidia fasciculata kinetoplast DNA replication proteins during the cell cycle. J. Cell Biol. 143:1998;911-919
41. Wang Z., Englund P.T. RNA interference of a trypanosome topoisomerase II causes progressive loss of mitochondrial DNA. EMBO J. 20:2001;4674-4683
42. Das A., et al. An insight into the active site of a type I DNA topoisomerase from the kinetoplastid protozoan Leishmania donovani. Nucleic Acids Res. 30:2002;794-802
43. Cheng C., et al. Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases. Cell. 92:1998;841-850
44. Wang J.C. DNA topoisomerase as targets of therapeutics: an overview. Adv. Pharmacol. 29A:1994;1-9
45. Ulukan H., Swaan P.W. Camptothecins: a review of their chemotherapeutic potential. Drugs. 62:2002;2039-2057
46. Kim D.K., Lee N. Recent advances in topoisomerase I-targeting agents, camptothecin analogues. Mini Rev. Med. Chem. 2:2002;611-619
47. Grabowski D.R., et al. Altered drug interaction and regulation of topoisomerase IIβ: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide. Mol. Pharmacol. 56:1999;1340-1345
48. Snyder R.D. Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons. Drug Chem. Toxicol. 26:2003;15-22
49. Lewy D.S., et al. Fostriecin: chemistry and biology. 2002. Curr. Med. Chem. 9:2002;2005-2032
50. Ray S., et al. Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani. J. Nat. Prod. 59:1996;27-29
51. Ray S., et al. Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol. Pharmacol. 54:1998;994-999
52. Figgitt D., et al. In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents. Antimicrob. Agents Chemother. 36:1992;1644-1647
53. Werbovetz K.A., et al. Cleavable complex formation in Leishmania chagasi treated with anilinoacridines. Mol. Biochem. Parasitol. 65:1994;1-10
54. Slunt K.M., et al. Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob. Agents Chemother. 40:1996;706-709
55. Shapiro T.A., Englund P.T. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc. Natl. Acad. Sci. U. S. A. 87:1990;950-954
56. Shapiro T.A., et al. Drug-promoted cleavage of kinetoplast DNA minicircles. Evidence for type II topoisomerase activity in trypanosome mitochondria. J. Biol. Chem. 264:1989;4173-4178
57. Nenortas E., et al. Antitrypanosomal activity of fluoroquinolones. Antimicrob. Agents Chemother. 43:1999;2066-2068
58. Keiser J., Burri C. Evaluation of quinolone derivatives for antitrypanosomal activity. Trop. Med. Int. Health. 6:2001;369-389
59. Nenortas E., et al. Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrob. Agents Chemother. 47:2003;3015-3017
60. Pate P.G., et al. Novobiocin antagonism of amastigotes of Trypanosoma cruzi growing in cell-free medium. Antimicrob. Agents Chemother. 29:1986;426-431
61. Gonzales-Perdomo M., et al. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob. Agents Chemother. 34:1990;1707-1714
62. Loiseau P.M. Action of DNA-gyrase inhibiting derivatives of 4-oxo-1, 4-dihydro-3-pyridinecarboxylic acid against Trypanosoma brucei. Int. J. Parasitol. 25:1995;403-405
63. Obexer W., et al. Activity and structure relationship of acridine derivatives against African trypanosomes. Trop. Med. Parasitol. 46:1995;49-53
64. Yamashita Y., et al. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem. Pharmacol. 39:1990;737-744
65. Mittra B., et al. Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol. Med. 6:2000;527-541
66. Ray S., et al. Dual inhibition of DNA topoisomerases of Leishmania donovani by novel indolylquinolines. Biochem. Biophys. Res. Commun. 230:1997;171-175
67. Chowdhury A.R., et al. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med. Sci. Monit. 8:2002;BR254-BR265
68. Kashiwada Y., et al. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J. Med. Chem. 39:1996;1016-1017
69. Chowdhury A.R., et al. Dihydrobetulinic acid induces apoptosis in Leishmania donovani by primarily targeting DNA topoisomerase I and II: implications in antileishmanial therapy. Mol. Med. 9:2003;26-36